is retatrutide bad Retatrutide: breakthrough… or still too early?, an investigational triple-hormone receptor agonist (GLP-1 + GIP + glucagon) designed to go beyond current metabolic therapies by What is Retatrutide and How

Lancet 406 , 26312643 (2025)

Retatrutide's basket trial design evaluating one molecule across obesity, OSA, and OA simultaneously is itself a statement about how the field is evolving

Total time: 5-7 minutes including preparation and hold time

Survodutide has shown glycemic improvement in Phase 2 trials with T2D patients (up to 1.71 percentage point HbA1c reduction at 16 weeks with the 2.7 mg dose), but this data is from shorter, smaller studies

Numerous studies support the efficacy of GLP-1 agonists for weight loss both in patients with and without type 2 diabetes mellitus

During that time, the FDA used enforcement discretion, meaning it generally didnt crack down on sellers while the peptides were being evaluated